Compare INDP & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | HQI |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | 75000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 180.1M |
| IPO Year | 2021 | 2008 |
| Metric | INDP | HQI |
|---|---|---|
| Price | $1.08 | $17.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 103.7K | 18.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | N/A | ★ 73.08 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $30,640,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.46 |
| P/E Ratio | ★ N/A | $57.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.92 | $7.38 |
| 52 Week High | $8.57 | $19.01 |
| Indicator | INDP | HQI |
|---|---|---|
| Relative Strength Index (RSI) | 29.35 | 68.82 |
| Support Level | $0.92 | $10.22 |
| Resistance Level | $2.95 | N/A |
| Average True Range (ATR) | 0.18 | 1.22 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 5.83 | 72.03 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.